publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
highlight
rnabas
agonist
target
rigi
center
ongo
hunt
novel
panantivir
vaccin
adjuv
antitumor
strategi
therapeut
target
rigi
might
lead
rome
dacquin
kasumba
nathali
grandvaux
rigi
receptor
key
sensor
pathogenassoci
molecular
pattern
pamp
contain
viral
rna
transduc
downstream
signal
activ
antivir
immunomodulatori
respons
fifteen
year
research
put
center
ongo
hunt
novel
pharmacolog
panantivir
vaccin
adjuv
antitumor
strategi
current
knowledg
testifi
redund
also
distinct
function
mediat
rigi
open
opportun
use
specif
potent
nucleic
acid
agonist
critic
discuss
evid
remain
knowledg
gap
impact
choic
design
optim
rna
ligand
achiev
appropri
immunostimulatori
respons
limit
advers
effect
prophylact
therapeut
intervent
virus
cancer
human
retino
acidinduc
gene
rigi
like
receptor
rlr
see
glossari
patternrecognit
receptor
prr
play
key
role
cytosol
sens
rna
virus
recognit
viral
rna
viral
replic
intermedi
initi
innat
immun
respons
rlr
famili
compos
three
ubiquit
express
member
rigi
melanoma
differentiationassoci
protein
laboratori
genet
physiolog
three
rlr
possess
dexdhbox
rna
helicas
domain
ctermin
domain
ctd
rigi
harbor
ntermin
caspaserecruit
domain
card
necessari
signal
figur
upon
ligand
recognit
bind
rigi
undergo
conform
chang
render
card
domain
avail
homotyp
interact
membraneassoci
common
adaptor
mitochondri
antiviralsign
mav
protein
anchor
membran
mitochondria
peroxisom
mitochondrialassoci
endoplasm
reticulum
membran
mam
mav
activ
result
coordin
activ
transcript
factor
nuclear
factor
klightchain
enhanc
activ
b
cell
nfkb
interferon
regulatori
factor
irf
ikb
kinas
ikk
complex
abg
ikkrel
tankbind
kinas
tbk
ikk
kinas
respect
event
culmin
transcript
regul
type
iii
interferon
ifn
proinflammatori
cytokin
therebi
establish
antivir
immunoregulatori
state
figur
key
figur
initi
attempt
use
synthet
rna
immunostimul
improv
human
health
perform
use
polyinosin
polycytidyl
acid
poli
c
deriv
limit
success
advanc
knowledg
mechan
ligand
recognit
function
rlr
possibl
use
rlr
ligand
panantivir
vaccin
adjuv
antitumor
agent
gain
much
attent
studi
use
rigi
rna
agonist
accumul
although
length
structur
signatur
nucleotid
content
determin
bind
rigi
featur
account
specif
two
receptor
still
unknown
recent
research
unveil
diverg
function
mediat
rigi
addit
knowledg
necessari
make
inform
choic
appropri
ligandbas
strategi
specif
therapeut
prophylact
clinic
applic
rigi
polymorph
alter
ligand
recognit
result
spontan
interferon
signatur
associ
inflammatori
autoimmun
diseas
polymorph
certainli
shape
respons
patient
rlrtarget
strategi
adjuv
molecul
potenti
host
immun
respons
antigen
agonist
molecul
trigger
physiolog
respons
bound
receptor
autoimmun
diseas
condit
immun
system
produc
antibodi
attack
healthi
tissu
host
caspaserecruit
domain
card
motif
found
mani
protein
involv
inflamm
apoptosi
mediat
homotyp
interact
two
protein
cytokin
small
protein
releas
cell
commun
cell
gainoffunct
gof
mutat
type
mutat
gene
result
alter
protein
exhibit
new
function
increas
activ
helicas
protein
capabl
unwind
nucleic
acid
hydrolysi
atp
homotyp
interact
interact
similar
domain
found
interact
protein
partner
immunostimul
molecul
capabl
boost
immun
respons
inflammasom
intracellular
multiprotein
complex
trigger
inflammatori
respons
activ
thiol
proteas
caspas
notabl
result
product
matur
interleukin
il
induc
cell
death
pyroptosi
interferon
ifn
subgroup
cytokin
produc
host
cell
respons
infect
act
infect
cell
surround
cell
trigger
induct
gene
encod
protein
antivir
activ
melanoma
differentiationassoci
protein
cytoplasm
prr
sens
viral
rna
viral
rna
intermedi
whose
activ
lead
cytokin
product
panhandl
form
secondari
structur
found
rna
molecul
aris
pair
complementari
sequenc
end
strategi
suffer
limit
avail
divers
pharmacolog
usabl
ligand
howev
import
function
diverg
rigi
recent
report
potenti
provid
new
therapeut
opportun
address
recent
concept
remain
gap
knowledg
regard
similar
differ
rigi
ligand
signal
biolog
function
highlight
knowledg
consid
choic
design
specif
potent
nucleic
acid
agonist
discuss
option
target
rigi
andor
achiev
best
antivir
immunomodulatori
respons
therapeut
vaccin
adjuv
develop
rlr
recogn
rna
speci
carri
pathogenassoci
molecular
pattern
pamp
characterist
select
rigi
ligand
recent
review
thu
highlight
recent
advanc
concept
relev
design
select
potent
rigi
agonist
use
vitro
transcrib
ivt
viral
rna
analog
determin
consensu
minimum
rna
size
requir
rigi
recognit
signal
transduct
short
bp
maximum
size
bind
rigi
suppress
remain
unknown
contrast
gener
accept
sens
high
molecular
weight
hmw
rna
speci
although
minimum
length
ligand
remain
unresolv
lengthdepend
induct
ifn
ivt
doublestrand
ds
rna
rigidefici
murin
embryon
fibroblast
mef
suggest
ligand
short
bp
activ
elucid
structur
mechan
rlr
activ
provid
key
inform
help
explain
rigi
ligand
length
discrimin
long
dsrna
speci
serv
scaffold
facilit
cooper
assembl
long
polym
therebi
facilit
optim
interact
expos
multipl
card
mav
hand
rigi
form
shorter
signalingcompet
ligandbound
filament
vitro
biochem
analys
indic
filament
nucleat
intern
region
propag
toward
end
dsrna
rigi
exhibit
endcap
pattern
oligomer
shorter
filament
although
observ
support
hypothesi
filament
dynam
explain
differ
rigi
oligomer
capac
signal
rna
duplex
differ
length
might
overli
simplist
consid
filament
format
atpdepend
bind
monom
rigi
triphosph
ppp
termin
region
short
ivt
dsrna
suffici
optim
signal
transduct
specul
rigi
filament
format
hmw
dsrna
would
energydemand
less
effici
helicas
ctd
pathogenassoci
molecular
pattern
pamp
molecular
signatur
uniqu
pathogen
recogn
danger
signal
prr
host
cell
induc
immun
respons
patternrecognit
receptor
prr
group
receptor
recogn
molecular
pattern
uniqu
pathogen
induc
immun
respons
polydispers
measur
molecular
weight
distribut
polydispers
poli
c
solut
mean
chain
length
vari
lead
mixtur
particl
differ
size
retino
acidinduc
gene
rigi
cytoplasm
prr
sens
viral
rna
viral
rna
intermedi
activ
lead
cytokin
product
rna
cap
addit
cap
structur
mrna
eukaryot
cell
protect
degrad
host
exonucleas
facilit
recruit
translationprotein
factor
structur
consist
connect
first
nucleotid
structur
form
addit
methyl
group
second
hydroxyl
group
first
ribos
sugar
rigi
sensor
respect
activ
ppp
low
molecular
weight
lmw
high
molecular
weight
hmw
viral
rna
viral
intermedi
contain
doublestrand
ds
rna
structur
ligand
bind
addit
ligand
length
rna
structur
modif
must
also
taken
consider
synthesi
specif
highaffin
rigi
agonist
salient
chemic
featur
rigi
engag
consist
higherord
structur
form
rna
duplex
panhandl
ppp
moieti
although
ivt
singlestrand
ss
rna
synthes
use
bacteriophag
polymeras
activ
rigidepend
ifn
product
import
consid
phage
polymeras
produc
transcript
contain
ppp
region
higherord
structur
result
copyback
mechan
dsrna
structur
ligand
also
essenti
activ
ppp
requir
furthermor
research
aim
understand
mechan
select
recognit
nonself
versu
selfrna
rigi
also
provid
insight
impact
rna
cap
omethyl
crucial
abolish
bind
rigi
selfrna
omethyl
mrna
also
prevent
detect
mechan
use
coronavirus
evad
recognit
comparison
unmodifi
rna
rna
contain
modifi
nucleotid
present
human
transcriptom
pseudouridin
fluorodeoxyribos
show
modifi
nucleotid
suppress
rigi
bind
signal
although
differ
mechan
howev
remain
determin
modif
alter
activ
addit
open
question
concern
contribut
nucleotid
composit
specif
effici
rigi
bind
activ
first
suggest
role
nucleotid
sequenc
came
observ
poli
uuc
region
untransl
region
utr
hepat
c
viru
hcv
viral
rna
correspond
polyacontain
rna
replic
intermedi
confer
capac
function
bind
rigi
reduct
au
content
rna
impair
rigi
activ
similarli
modif
nucleotid
sequenc
ivt
ppp
rna
potenti
activ
rigidepend
antivir
inflammatori
activ
without
alter
ligand
specif
measl
viru
infect
deep
sequenc
reveal
rna
speci
crosslink
rigi
enrich
aurich
rna
speci
au
content
posit
correl
immunostimulatori
capac
although
support
import
rna
sequenc
rlr
activ
remain
unclear
nucleotid
sequenc
impact
specif
bind
rigi
andor
overal
ligand
length
remain
discrimin
paramet
current
use
design
specif
rigi
agonist
pharmacolog
applic
seem
clear
howev
futur
develop
need
take
account
length
also
higherord
structur
sequenc
rna
modif
futur
work
aim
character
impact
combin
thereof
rigi
bind
well
abil
engag
downstream
signal
rational
behind
search
specif
ligand
reli
accumul
evid
strike
function
differ
rigi
first
observ
major
result
cardmedi
interact
mitochondri
antiviralsign
mav
adaptor
mav
activ
result
coordin
activ
nfkb
transcript
factor
nfkb
activ
ikk
abg
kinas
complex
part
mediat
pathway
activ
depend
ikkrel
kinas
turn
regul
transcript
type
orang
sphere
type
iii
interferon
ifn
blue
sphere
well
proinflammatori
cytokin
purpl
sphere
includ
doubl
invert
pink
triangl
rigi
also
mediat
activ
inflammasom
subsequ
activ
purpl
cylind
lead
product
matur
pink
triangl
also
involv
regul
noncanon
nfkb
pathway
sustain
activ
interf
proteasomemedi
degrad
mechan
current
uncharacter
depict
question
mark
abbrevi
p
phosphoryl
u
ubiquitin
differ
aros
attempt
gener
rlrspecif
knockout
mice
mice
strain
commonli
use
studi
antivir
immun
respons
wherea
mice
healthi
without
notic
defect
rigidefici
mice
exhibit
high
embryon
mortal
growth
retard
death
within
week
birth
fetal
liver
degener
gener
viabl
rigidefici
mous
model
requir
backcross
onto
strain
wide
use
genet
flexibl
rigidefici
mice
spontan
develop
patholog
phenotyp
lead
coliti
none
phenotyp
report
mice
singlenucleotid
polymorph
snp
encod
rigi
respect
associ
variou
clinic
inflammatori
autoimmun
present
suggest
import
function
redund
also
like
differ
figur
sever
gainoffunct
gof
mutat
associ
singletonmerten
syndrom
sm
box
although
variabl
clinic
featur
recent
review
box
rare
genet
multisystem
disord
common
symptom
includ
limit
tooth
abnorm
calcif
major
arteri
aorta
reduc
bone
densiti
affect
limb
atrophi
abnorm
develop
gener
sm
classifi
either
classic
atyp
larg
major
patient
exhibit
typic
clinic
present
howev
patient
exhibit
sm
symptom
normal
dentit
report
case
sm
classifi
atyp
sm
rare
neurolog
development
genet
disord
caus
sever
mental
physic
handicap
describ
earlyonset
disord
nervou
system
rapid
progress
toward
veget
state
death
ag
patient
exhibit
among
phenotyp
sign
encephalopathi
includ
radiolog
abnorm
white
matter
increas
number
lymphocyt
cerebrospin
fluid
csf
relev
sign
symptom
includ
brain
atrophi
increas
level
type
interferon
ifni
csf
well
abnorm
enlarg
liver
skin
lesion
system
multiorgan
autoimmun
disord
heterogen
diseas
manifest
organ
affect
includ
skin
rash
chronic
fatigu
arthriti
sever
glomerulonephr
neurolog
impair
loss
immun
toler
selfantigen
sle
autoimmun
result
dysregul
multipl
cellular
compon
includ
sever
proinflammatori
cytokin
notabl
type
interferon
disrupt
clearanc
apoptot
wast
immunocomplex
presenc
autoantibodi
abnorm
complement
pathway
disrupt
lymphocyt
immun
respons
also
call
insulindepend
diabet
type
diabet
chronic
condit
pancrea
produc
suffici
insulin
hormon
necessari
cellular
uptak
metabol
glucos
result
accumul
glucos
bloodstream
henc
caus
symptom
extrem
fatigu
weight
loss
frequent
urin
blur
vision
etc
complic
result
type
diabet
result
death
diabet
patient
need
receiv
recombin
insulin
rest
life
also
call
toxic
diffus
goiter
grave
diseas
common
caus
hypothyroid
significantli
affect
qualiti
life
clinic
manifest
depend
age
patient
time
hypothyroid
onset
includ
limit
weight
loss
weak
muscl
irrit
anxieti
sleep
problem
eye
problem
swell
pain
red
doubl
vision
intriguingli
gof
mutat
found
patient
phenotyp
indic
ag
also
system
lupu
erythematosu
sle
box
similarli
variant
identifi
risk
factor
type
diabet
sle
grave
diseas
box
missens
mutat
affect
helicas
domain
associ
increas
ifni
signatur
direct
evid
link
rlr
gofassoci
ifni
upregul
inflammatori
autoimmun
phenotyp
current
limit
howev
lupuslik
symptom
observ
mous
model
harbor
associ
spontan
ifni
induct
multipl
organ
abolish
mavsor
ifni
receptordefici
background
thu
provid
first
direct
link
gof
mutat
autoimmun
phenotyp
structur
analys
rigi
led
propos
model
atyp
smscaus
mutat
affect
helicas
domain
inhibit
rigi
atpas
function
therebi
reliev
inhibitori
mechan
prevent
rigi
activ
endogen
selfrna
whether
mechan
explain
constitut
activ
diseasecaus
mutat
affect
atpas
domain
remain
determin
altern
model
propos
agscaus
mutat
result
increas
dsrna
avid
constitut
activ
endogen
rna
recognit
howev
view
challeng
distinct
agscaus
mutat
found
lose
ligand
respons
atpas
activ
singl
rlr
gene
mutat
associ
constitut
increas
ifni
signatur
lead
distinct
inflammatori
autoimmun
diseas
still
puzzl
futur
studi
use
novel
mous
model
aim
understand
mechan
underli
specif
diseasecaus
mutat
rigi
demonstr
causal
effect
variou
polymorph
structur
similar
rigi
well
welldocu
signal
common
adaptor
mav
initi
led
consensu
view
rigi
provid
multipl
redund
immun
mechan
offer
effect
protect
host
concept
support
observ
sever
virus
includ
paramyxovirida
sendai
viru
sev
measl
viru
mev
pneumovirida
respiratori
syncyti
viru
rsv
flavivirida
west
nile
viru
wnv
dengu
viru
denv
reovirida
rotaviru
engag
rigi
trigger
ifn
respons
howev
accumul
evid
reveal
distinct
pathway
regul
rigi
figur
engag
rlr
well
document
activ
nfkb
transcript
factor
cooper
initi
express
antivir
proinflammatori
cytokin
essenti
limit
viru
replic
spread
recent
work
yield
data
support
tempor
involv
rigi
initi
durat
cytokin
respons
mous
model
sev
infect
requir
ifni
iii
tumor
necrosi
factor
tnf
ifng
express
late
day
earlier
day
time
infect
vitro
rigi
involv
initi
essenti
persist
antivir
express
induc
rsv
tempor
involv
might
either
reflect
abil
rlr
activ
distinct
yet
identifi
signal
pathway
downstream
mav
gener
rigi
pamp
differ
time
viral
replic
support
latter
sens
wnv
infect
rigi
demonstr
depend
distinct
viral
rna
speci
accumul
differ
kinet
hand
context
sev
rsv
infect
activ
depend
rigi
wherea
essenti
dampen
ubiquitin
subsequ
proteasomemedi
degrad
figur
proinflammatori
arm
rlrdepend
respons
also
subject
specif
sensor
regul
rigi
requir
rsvinduc
nfkb
activ
howev
rigi
act
upstream
classic
ikbadepend
nfkb
pathway
typic
respons
rapid
transient
nfkb
activ
figur
point
distinct
role
regul
nfkb
respons
noncanon
pathway
addit
rigi
induc
activ
nfkbdepend
transcript
proinflammatori
interleukin
il
mavsdepend
pathway
involv
interact
cardcontain
adaptor
wellknown
activ
apoptosi
nfkb
signal
interestingli
rigi
trigger
inflammasom
assembl
activ
cleavag
ultim
result
extracellular
product
matur
bioactiv
figur
thu
rigi
play
distinct
role
induct
durat
antivir
inflammatori
respons
overal
understand
redund
diverg
rigi
function
still
spars
much
remain
learn
fulli
comprehend
consequ
therapeut
activ
rigi
avail
data
hold
great
promis
use
specif
rigi
ligand
novel
panantivir
vaccin
adjuv
potenti
anticanc
immunotherapi
also
highlight
knowledg
gap
challeng
remain
address
mani
studi
report
use
rigi
ligand
preclin
studi
specif
rigi
tolllik
receptor
tlr
demonstr
agonist
discuss
hereaft
intracellular
deliveri
ivt
ppp
rna
deriv
utr
vesicular
stomat
viru
vsv
vsvutr
ppprnainduc
antivir
inflammatori
transcript
program
significantli
protect
cell
influenza
viru
iav
vsv
denv
hcv
human
immunodefici
viru
hiv
chikungunya
viru
chikv
vitro
ex
vivo
vivo
vsvutr
ppprna
moder
protect
mice
iav
modif
intern
rna
sequenc
yield
optim
agonist
increas
antivir
activ
iav
chikv
tabl
altern
synthet
rigispecif
agonist
compos
bent
rna
form
gu
wobbl
base
pair
mimick
structur
iav
panhandl
promot
exhibit
potent
antivir
activ
iav
iav
resist
antivir
drug
oseltamivir
vitro
well
strong
adjuv
potenti
vivo
mice
incorpor
inactiv
iav
vaccin
addit
trigger
signific
tumor
regress
murin
pancreat
tumor
model
indic
potenti
cancer
immunotherapeut
third
type
rigi
agonist
form
ppp
rna
harbor
stemloop
recent
found
induc
greater
ifni
respons
compar
poli
c
vivo
howev
remain
test
prophylact
therapeut
context
difficulti
associ
templatedepend
synthesi
hmw
rna
ad
poorli
defin
specif
featur
ligand
limit
larg
major
studi
use
hmw
poli
c
analog
late
hmw
poli
c
evalu
immunostimul
vivo
littl
success
stabl
deriv
poli
ic
lc
obtain
modif
polyllysin
carboxymethyl
cellulos
success
use
mice
prophylact
therapeut
protect
broad
spectrum
human
virus
includ
lethal
sever
acut
respiratori
syndrom
coronaviru
sarscov
lethal
iav
rsv
tabl
incorpor
poli
ic
lc
adjuv
also
enhanc
clinic
effici
experiment
vaccin
patient
recurr
malign
glioma
ovarian
cancer
pancreat
cancer
undefin
structur
heterogen
polydispers
hmw
poli
c
analog
togeth
unpredict
pharmacokinet
toxic
present
hurdl
therapeut
use
identifi
novel
structur
defin
ligand
attract
avenu
develop
new
therapeut
toward
two
natur
hmw
dsrna
recent
report
tabl
dsrna
rbdsrna
correspond
genom
endornaviru
extract
rice
bran
found
sever
plant
significantli
reduc
mortal
morbid
caus
iav
sev
respect
mice
nucleic
acid
band
dsrna
correspond
yeast
viru
totoviridia
famili
induc
stronger
ifni
respons
compar
poli
c
ex
vivo
strongli
increas
efficaci
attenu
poxviru
modifi
vaccinia
viru
ankara
mva
base
vaccin
target
cancer
cell
express
vaccin
antigen
mice
howev
data
agonist
interpret
caution
relat
impact
specif
stimul
poli
c
analog
rbdsrna
concomitantli
activ
associ
strong
inflammatori
respons
complex
formul
jetpei
transfect
reagent
success
use
vivo
mice
intracellular
deliveri
rigi
ligand
bypass
activ
tabl
approach
would
worth
test
ligand
preclin
studi
howev
applic
strategi
specif
engag
rlr
human
trial
remain
challeng
although
studi
start
build
case
benefici
therapeut
usag
specif
rigi
agonist
evid
miss
make
inform
choic
best
ligand
trigger
appropri
respons
particular
applic
compar
analys
antivir
immunomodulatori
activ
rigi
agonist
variou
tumor
virus
anim
human
instruct
effici
antivir
respons
sever
virus
involv
rlr
sensor
furthermor
ectop
express
vitro
prolong
rigidepend
activ
suggest
dual
engag
rigi
potenti
trigger
sustain
antivir
respons
therefor
one
could
specul
strategi
target
rigi
could
provid
therapeut
advantag
complet
assess
hypothesi
limit
avail
ligand
proven
capabl
equal
activ
rlr
strategi
mix
rigi
ligand
would
like
bias
differ
rate
stabil
uptak
ligand
host
cell
moreov
design
univers
rlr
ligand
turn
hamper
incomplet
knowledg
common
pamp
signatur
advantag
use
rigi
ligand
ifn
panantivir
question
worth
discuss
recent
studi
highlight
differ
contribut
ifni
ifniii
antivir
respons
extens
clinic
use
ifni
clearli
document
doserel
advers
event
highlight
deleteri
effect
increas
prolong
ifni
respons
howev
clinic
trial
use
ifniii
patient
chronic
hcv
infect
report
antivir
activ
similar
ifni
fewer
system
advers
effect
like
owe
restrict
distribut
ifniii
receptor
therefor
type
iii
respons
seem
favor
type
respons
antivir
applic
ifni
iii
transcript
signatur
induc
vitro
vsvderiv
ppprna
rigi
ligand
tabl
balanc
two
respons
remain
fulli
evalu
vivo
ligand
tabl
select
induc
high
ifni
gene
express
associ
weak
type
ifniii
respons
balanc
opposit
trigger
poli
c
although
data
use
poli
c
recogn
suggest
favor
ifn
balanc
antivir
applic
evid
use
ligand
yet
avail
studi
clarifi
relev
balanc
ifni
iii
qualiti
antivir
immun
necessari
determin
best
ratio
therapeut
indic
whether
achiev
use
rlr
ligand
idea
induc
physiolog
relev
level
ifn
activ
signal
pathway
lead
transcript
control
endogen
ifn
gene
might
also
limit
deleteri
effect
observ
exogen
ifn
mind
altern
approach
rlr
ligand
current
earli
stage
investig
use
agonist
induc
ifn
respons
use
rlr
ligand
howev
present
particular
induc
proinflammatori
respons
addit
trigger
induct
ifn
inflamm
although
necessari
resolv
viru
infect
also
respons
diseas
pathogenesi
strength
durat
respons
strictli
control
major
gap
knowledg
need
address
appropri
pharmacolog
use
specif
rlr
rna
agonist
concern
benefici
versu
undesir
effect
induc
inflammatori
respons
identif
snp
human
greater
extent
teach
us
uncontrol
activ
rlr
associ
onset
chronic
inflammatori
autoimmun
diseas
figur
studi
necessari
thoroughli
evalu
rigiandor
agonist
provid
immunostimulatori
effect
vivo
expens
system
elev
cytokin
respons
respons
longlast
advers
effect
moreov
inflammasom
respons
also
analyz
care
although
benefici
also
promot
hyperinflamm
cell
death
whether
rigi
ligandinduc
inflammasom
activ
would
provid
advantag
induc
advers
effect
noninflammasom
activ
strategi
question
worth
address
less
two
decad
first
report
character
role
rlr
immun
closer
ever
rlr
ligand
clinic
applic
pilot
trial
ongo
clinic
trial
human
yield
promis
result
notabl
cancer
immunotherapi
although
come
long
way
key
mileston
reach
still
signific
knowledg
gap
need
fill
use
molecular
cellular
structur
biolog
approach
abl
design
exclus
potent
rigi
ligand
also
decid
appropri
target
use
antivir
vaccin
adjuv
cancer
immunotherapeut
applic
see
outstand
question
discuss
accumul
evid
demonstr
distinct
function
induc
follow
rigi
engag
opin
function
diverg
need
consid
choic
agonist
therapeut
purpos
instanc
although
ligandinduc
cell
death
might
associ
advers
effect
antivir
applic
might
benefici
cancer
therapeuticswher
could
har
induc
tumor
cell
death
conjunct
stimul
antitumor
immun
achiev
need
systemat
thorough
character
specif
ligand
use
preclin
studi
also
allow
determin
pro
con
target
rigi
two
simultan
fail
might
yield
incomplet
pictur
clinic
relev
effici
ligandbas
strategi
consid
largescal
clinic
trial
commerci
final
era
person
medicin
aim
use
tailormad
drug
uniqu
genet
profil
instead
onesizefitsal
medicin
one
would
think
specif
ligand
rigi
would
provid
rang
option
patient
receptor
genet
polymorph
could
affect
ligand
bind
featur
rna
ligand
allow
synthesi
rigiand
agonist
maximum
ligand
length
requir
rigi
activ
minimum
length
bind
nucleotid
sequenc
intern
nucleotid
modif
alter
affin
rigi
ligand
function
underli
mechan
specif
mediat
rigi
could
knowledg
har
develop
appropri
antivir
vaccin
adjuv
cancer
immunotherapeut
necessari
avoid
engag
everi
rlrtarget
strategi
necessari
formul
allow
intracellular
deliveri
rlr
agonist
clinic
applic
human
would
strategi
specif
target
either
rigi
advantag
simultan
engag
rigi
context
particular
prophylact
therapeut
applic
extent
would
rlr
ligand
provid
effici
antivir
therapeut
effect
given
infect
would
window
therapeut
opportun
rlr
ligand
appropri
countermeasur
farm
industri
limit
spread
virus
influenza
outbreak
swine
poultri
distinct
rigi
polymorph
associ
increas
ifn
respons
result
differ
autoimmun
inflammatori
diseas
predict
advers
effect
could
result
clinic
use
ligandmedi
activ
rigi
polymorph
impact
respons
patient
rlr
ligand
